<DOC>
	<DOCNO>NCT00747695</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics , pharmacodynamics safety rabeprazole single multiple daily administration child age 1 11 year , inclusive , GERD .</brief_summary>
	<brief_title>A Pharmacokinetic Safety Study Single Multiple Doses Rabreprazole Pediatric Patients With Gastroesophageal Reflux Disease ( GERD ) 1 11 Years Old , Inclusive</brief_title>
	<detailed_description>This open-label ( physician patient know name study medication ) , multi-center , Phase 1 study , consist 2 part . The first part study non-randomized , patient receive dose . In second part study , patient randomize ( study medication assign chance ) 2 dose group . The purpose study evaluate pharmacokinetics , pharmacodynamics ( clinical global impression formulation palatability ) safety rabrepazole single multiple daily administration 2 dose level child age 1 11 year , inclusive , GERD . As study exploratory assessment pharmacokinetics , pharmacodynamics safety rabeprazole child , formal hypothesis test apply . Safety tolerability , include monitor adverse event , clinical laboratory result , physical examination , vital sign ECG measurement , evaluate throughout study . Patients receive rabeprazole sodium single daily oral dos 5 successive day bead formulation . Patients first part study receive single multiple daily every 24 hour dose 0.14 mg/kg , use increment 1 mg dose . Safety pk data part 1 study determine 2 dosage study part 2 study .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>Boy girl minimum weight 10 kg endoscopically prove GERD include endoscopic examination part diagnostic evaluation Patients treat , currently receive proton pump inhibitor ( PPI ) , H2 blocker , antacid eligible ( long go antacids 24 hour , PPIs H2 blocker 3 day prior dose , except cimetidine , must discontinue least 7 day prior dose ) remain medication treatment period Patients generally healthy , presence GERD , exception following : Patients stable asthma/reactive airway disease cystic fibrosisdependent GERD symptoms stable treatment regimens subject stable dos allergy attention deficit disorder medicine . Patients history current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder , lipid abnormality , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers exclude subject could interfere interpretation study result Primary pulmonary ENT symptom Presence `` warning signal '' , suggest cause vomiting/regurgitation GERD History primary esophageal motility disorder systemic condition affect esophagus History eosinophilic esophagitis , persistent milk protein allergy , allergic gastroenteropathy History current presence peptic ulcer Current presence Helicobacter pylori History definitive acidlowering surgery Significant arrhythmia .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Pediatric Pharmacokinetics</keyword>
	<keyword>Pediatric Pharmacodynamics</keyword>
	<keyword>Rabeprazole</keyword>
	<keyword>Pediatric GERD</keyword>
	<keyword>Aciphex</keyword>
</DOC>